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G protein-coupled receptors (GPCRs), G proteins and adenylyl cyclase (AC) comprise one of
the most studied transmembrane cell signaling pathways. However, it is unknown whether
the ligand-dependent interactions between these signaling molecules are based on random
collisions or the rearrangement of pre-coupled elements in a macromolecular complex.
Furthermore, it remains controversial whether a GPCR homodimer coupled to a single
heterotrimeric G protein constitutes a common functional unit. Using a peptide-based
approach, we here report evidence for the existence of functional pre-coupled complexes of
heteromers of adenosine A2A receptor and dopamine D2 receptor homodimers coupled to
their cognate Gs and Gi proteins and to subtype 5 AC. We also demonstrate that this
macromolecular complex provides the necessary frame for the canonical Gs-Gi interactions
at the AC level, sustaining the ability of a Gi-coupled GPCR to counteract AC activation
mediated by a Gs-coupled GPCR.
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Interactions between G protein-coupled receptors (GPCRs), Gαand Gβγ protein subunits and adenylyl cyclase (AC) have beenclassically analyzed in the frame of ‘collision-coupling’
mechanisms, which implies they are freely mobile molecules in
the plasma membrane able to couple by random collision.
Binding of an agonist to its GPCR induces the binding and
subsequent activation of the heterotrimeric G protein, which
leads to the dissociation of Gα and Gβγ subunits and binding of
free Gα subunit to AC, leading to its regulation1. However,
accumulating experimental evidence suggests that GPCR activa-
tion commonly occurs without dissociation of the receptor from
its G protein, without G-protein subunit dissociation and even
with pre-coupling of the heterotrimeric G protein to AC
(reviewed in ref.2). Moreover, growing evidence suggests that the
pentameric complex formed by one GPCR homodimer (two
identical protomers) and one heterotrimeric G protein constitutes
a common GPCR functional unit3–6. Therefore, classical GPCR
physiology needs to be revisited in the frame of pre-coupling
mechanisms and GPCR oligomerization.
The topology of mammalian transmembrane AC consists of a
variable cytoplasmic N terminus (NT) and two large cytoplasmic
domains, C1 and C2, separated by two membrane-spanning
domains, M1 and M2, each comprising six putative transmem-
brane domains (TMs)7. C1 and C2 interact to form the enzyme
catalytic core at their interface and their arrangement allows, at
least in theory, the simultaneous binding of their external sides to
Gsα and Giα8, providing the structural framework for the cano-
nical antagonistic interaction between Gs-coupled and Gi-
coupled receptors at the AC level of speciﬁc AC isoforms,
including AC1, AC5, and AC62,7. Gsα subunit binds to C2 and
increases the afﬁnity of C1 and C2, promoting catalysis, while
Giα, by binding to C1, works in the opposite direction and
counteracts AC activation7.
It is becoming accepted that GPCRs can form heteromers6,9,
deﬁned as macromolecular complexes composed of at least two
different protomers with biochemical properties that are
demonstrably different from those of its individual compoments6.
Considering homodimers as main functional GPCR units, het-
eromers could be viewed as constituted by different interacting
homodimers6. Of special functional signiﬁcance could be those
heteromers constituted by one homodimer coupled to a Gs/olf
(Gs for short) protein and another different homodimer coupled
to a Gi/o (Gi for short) protein. Our hypothesis is that such a
“GPCR heterotetramer” would be part of a pre-coupled macro-
molecular complex that also includes AC, a necessary frame for
the canonical antagonistic interaction at the AC level. Recent
studies have provided experimental evidence for the existence of
GPCR heterotetramers that fulﬁll this scheme, like the adenosine
A2A-dopamine D2 receptor (A2AR–D2R) heterotetramer10. In the
present study, using interfering peptides with amino acid
sequences of TMs of adenosine A2AR and D2R and putative TMs
of AC5, we provide evidence for the existence of functional pre-
coupled complexes of A2AR and D2R homodimers, their cognate
Gs and Gi proteins and AC5, and demonstrate that this macro-
molecular complex provides the sufﬁcient but necessary condi-
tion for the canonical Gs–Gi interactions at the AC level.
Results
Symmetrical TM interfaces in the A2AR-D2R heterotetramer.
To identify the arrangement of A2AR and D2R protomers in the
heterotetramer (TMs involved in the homo and heterodimeriza-
tion interfaces), we used synthetic peptides with the amino acid
sequence of TMs 1–7 of A2AR and D2R (TMs and TM peptides
are abbreviated TM 1, TM 2, … and TM1, TM2, … respectively)
fused to the HIV transactivator of transcription (TAT) peptide,
which determines the orientation of the peptide when inserted in
the plasma membrane (see ref.11 and Methods section). Peptides
were ﬁrst tested in bimolecular ﬂuorescence complementation
(BiFC) experiments, in HEK-293T cells expressing receptors
fused to two complementary halves of YFP (Venus variant; cYFP
and nYFP). Functionality of all fused receptors was shown with
cAMP accumulation experiments (Supplementary Fig. 1).
Fluorescence was detected when cells were transfected with
A2AR-nYFP and A2AR-cYFP cDNA (broken lines in Fig. 1a) or
with D2R-nYFP and D2R-cYFP cDNA (broken lines in Fig. 1b),
indicating the formation of both A2AR-A2AR and D2R-D2R
homodimers. Notably, when BiFC assay was performed in
the presence of TM peptides (Fig. 1a, b), ﬂuorescence
complementation of A2AR-nYFP and A2AR-cYFP was only
signiﬁcantly reduced in the presence of TM6 of A2AR (Fig. 1a; see
Methods and Supplementary Fig. 2 for justiﬁcation of the optimal
concentration and time of incubation of the TM peptides).
Similarly, only TM6 of D2R reduced ﬂuorescence complementa-
tion of D2R-nYFP and D2R-cYFP (Fig. 1b). These results indicate
that TM 6 forms part of a symmetric interface for both A2AR and
D2R homodimers when expressed alone. The same results were
obtained in cells expressing A2AR-nYFP and A2AR-cYFP co-
transfected with non-fused D2R cDNA (Fig. 1a) or in cells
expressing D2R-nYFP and D2R-cYFP co-transfected with non-
fused A2AR cDNA (Fig. 1b). These results therefore indicate that
TM 6 also forms part of a symmetric interface for both A2AR and
D2R homodimers in the heterotetramer. Fluorescence was also
detected in cells expressing A2AR-nYFP and D2R-cYFP (broken
lines in Fig. 1c), indicating the formation of A2AR–D2R hetero-
mers. This ﬂuorescence was only signiﬁcantly reduced in the
presence of TM4 and TM5 of both A2AR and D2R (Fig. 1c),
suggesting a TMs 4/5 interface for A2AR and D2R heterodimer in
the heterotetramer. Additional evidence of heteromer formation
via TMs 4/5 was obtained from proximity ligation assay (PLA).
This technique permits the direct detection of molecular inter-
actions between two proteins without the need of fusion proteins.
A2AR–D2R heteromers were observed as red punctate staining in
HEK-293T cells expressing both A2AR and D2R (Supplementary
Fig. 3a–c). Pretreatment of cells with TM4 and TM5 of A2AR and
D2R but not with TM6 or TM7 (negative control), signiﬁcantly
decreased PLA staining (Supplementary Fig. 3d), decreasing the
number of stained cells and red spots per stained cell (Fig. 2a),
supporting TMs 4/5 as the interface of the A2AR–D2R heteromer.
In HEK-293T cells expressing both receptors, the A2AR agonist
CGS21680 (100 nM; minimal concentration with maximal effect)
signiﬁcantly increased basal cAMP and the D2R agonist quinpirole
(1 μM; minimal concentration with maximal effect) decreased
forskolin-induced cAMP (Fig. 2b). Pertussis toxin, by catalyzing
ADP-ribosylation of the alpha-subunit of Gi, impeded D2R-
mediated Gi activation and thus the ability of quinpirole to inhibit
forskolin-induced cAMP accumulation (Fig. 2b). Cholera toxin, by
selectively catalyzing ADP-ribosylation of the alpha-subunit of Gs
and leading to persistent AC stimulation, impeded an additional
effect of CGS21680 but left unaltered the Gi-mediated quinpirole-
induced inhibition of forskolin-induced cAMP accumulation
(Fig. 2b). These results support the coupling of A2AR and D2R to
their respective cognate Gs and Gi proteins in the A2AR–D2R
heterotetramer. We could then demonstrate that neither A2AR or
D2R activation leads to rearrangements of the TM interfaces in the
A2AR–D2R heterotetramer, since, in the presence of CGS21680
(100 nM) or quinpirole (1 μM), ﬂuorescence in cells expressing
A2AR-nYFP and D2R-cYFP was still selectively reduced by TM4
and TM5 of A2AR and D2R (Fig. 1c). Similarly, A2AR activation by
CGS21680 (Fig. 1a) or D2R activation by quinpirole (Fig. 1b) did
not modify the corresponding speciﬁc homomer TM 6 interface
determined in ligand-free experiments.
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We then constructed a molecular model of the A2AR–D2R
heterotetramer (Fig. 1d), considering: (i) the crystal structures of
GPCRs and G proteins, as well as homology models (see Methods
section); (ii) the structural details of TM interfaces of GPCR
oligomers, observed in crystal structures12 as well as predicted by
molecular dynamics simulations (see Methods section); (iii) the
results from BiFC experiments with interfering TM peptides; (iv)
the general assumption of a common minimal functional unit of
GPCRs constituted by a homodimer coupled to its cognate G
protein (see Introduction section); (v) the suggested tetrameric
structure of the A2AR–D2R heteromer constituted by two
interacting homodimers, from previous results obtained with
bioluminescence resonance energy transfer (BRET) experiments
with complementation of both the donor and the acceptor
biosensors10; and (vi) the previously enunciated assumption
about the necessity of a simultaneous activation of Gs and Gi
coupled to the interacting catalytic domains of the same molecule
of AC for a canonical antagonistic interaction8. This resulted in
one minimal computational solution that accommodates the TMs
4/5 interface for A2AR–D2R heterodimerization and the TM 6
interface for both A2AR–A2AR and D2R–D2R homodimerization
(see Methods and Supplementary Fig. 4). The existence of these
interfaces implies two internal interacting A2AR and D2R
protomers and two external A2AR and D2R protomers in which
the α-subunits of Gi and Gs bind to the corresponding external
protomers of the D2R or A2AR homodimers. This would be the
only feasible conﬁguration to avoid any steric clash between the
two G proteins simultaneously bound to the complex. Finally, the
model also predicts a large distance between both βγ-subunits
(Fig. 1d).
Asymmetrical TM interfaces of the heterotetramer with AC5.
Although several studies have provided direct evidence for pre-
coupling between G protein subunits and AC7,13–15, speciﬁcally
with the AC NT7,14, to our knowledge, the existence of pre-
coupling between TMs of a GPCR and TMs of AC had not been
previously addressed. We ﬁrst analyzed the ability of AC5 to
establish direct intermolecular interactions with A2AR or D2R or
with A2AR–D2R heteromers via saturation BRET experiments in
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Fig. 1 Quaternary structure of A2AR-D2R heterotetramer coupled to Gs and Gi proteins. a–c BiFC experiments in HEK-293T cells transfected with A2AR-
nYFP (0.5 μg) and A2AR-cYFP (0.5 μg) cDNA in the absence or presence of D2R cDNA (0.5 μg) (a), with D2R-nYFP (0.75 μg) and D2R-cYFP (0.75 μg)
cDNA in the absence or the presence of A2AR cDNA (0.4 μg) (b) or with A2AR-nYFP (0.6 μg) and D2R-cYFP (0.6 μg) cDNA (c); cells were treated for 4 h
with medium (broken lines) or 4 μM of indicated TM peptides (numbered 1–7) of A2AR (green squares) or D2R (orange squares) before addition of
medium, CGS21680 (CGS; 100 nM) or quinpirole (Q; 1 μM); ﬂuorescence was detected at 530 nm and values (in means ± SEM) are expressed as
ﬂuorescence arbitrary units (n= 8, with triplicates); *, **, and *** represent signiﬁcantly lower values as compared to control values (p < 0.05, p < 0.01 and
p < 0.001, respectively; one-way ANOVA followed by Dunnett’s multiple comparison tests). d Computational model of the A2AR-D2R heterotetramer built
using the experimental interfaces predicted in panels (a–c) (TMs 4/5 for heterodimerization and TM 6 for homodimerization) with Gs and Gi binding to
the external protomers; schematic slice-representation (left) and the constructed molecular model (right; with the same color code as the schematic slice-
representation), viewed from the extracellular side
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the absence of ligands (results are always shown as means ±
SEM). Clear-cut saturation BRET curves were obtained with
HEK-293T cells transfected with a constant amount of A2AR
fused to Renilla Luciferase (A2AR-RLuc) cDNA and increasing
quantities of AC5 fused to YFP (AC5-YFP) cDNA (Fig. 3a;
BRETmax= 54 ± 6 mBU and BRET50= 42 ± 13) or with cells
transfected with a constant amount of D2R-RLuc cDNA and
increasing amounts of AC5-YFP cDNA (Fig. 3b; BRETmax= 38 ±
5 mBU and BRET50= 28 ± 14), indicating that AC5 interacts
with A2AR or D2R in the absence of ligands. Also, saturation
BRET curves were obtained when HEK-293T cells transfected
with A2AR-RLuc and increasing amounts of AC5-YFP cDNAs
were co-transfected with D2R cDNA (Fig. 3c; BRETmax= 39 ± 3
mBU and BRET50= 24 ± 8) or when cells transfected with D2R-
RLuc and increasing amount of AC5-YFP cDNAs were co-
transfected with A2AR cDNA (Fig. 3d; BRETmax= 30 ± 2 mBU
and BRET50= 20 ± 7). All saturation BRET curves were best-
ﬁtted to a monophasic model. We also veriﬁed that over-
expression of AC5 did not alter A2AR–D2R heteromerization with
BRET experiments in HEK-293T cells transfected with A2AR-
Rluc (0.4 μg) and D2R-YFP (0.6 μg) and increasing amounts of
AC5 cDNA. No BRET differences were observed between the
results obtained with 0, 0.3, 1.0 and 3.0 μg of AC5 cDNA (56 ± 7,
53 ± 6, 53 ± 3, and 52 ± 4 mBU, respectively). Altogether, these
results suggest that AC5 oligomerize with A2AR-D2R heteromers
in the absence of ligands.
Next, we performed BiFC assays in HEK-293T cells expressing
AC5-nYFP, A2AR-cYFP, and D2R (Fig. 3e) as well as AC5-nYFP,
D2R-cYFP and A2AR (Fig. 3f). Normal functionality of AC5-YFP
has been previously reported16. Signiﬁcant ﬂuorescence was
detected in all cases, providing additional support to direct
interactions between AC5 and A2AR–D2R heteromers (broken
lines in Fig. 3e, f). To determine the possible involvement of
receptor TMs in the A2AR–D2R heterotetramer-AC5 interface, we
performed BiFC experiments with all different A2AR (Fig. 3e) or
D2R (Fig. 3f) TM peptides. In the absence of ligands,
pretreatment of cells with TM1, TM5, or TM6 of A2AR
signiﬁcantly decreased complementation between AC5 and
A2AR (Fig. 3e, top panel). Similarly, pretreatment with TM1,
TM4, TM5, or TM6 of D2R signiﬁcantly decreased complemen-
tation between AC5 and D2R (Fig. 3f, top panel). This suggests a
discrete interaction between TM1 of both receptors with AC5.
Since TMs 4–5 of the inner receptor protomers and TMs 6 of
inner and outer receptor protomers participate in homo- and
heterodimerization (see above), respectively, their apparent
involvement in the interactions with AC5 must be indirect,
implying that the optimal interaction of the A2AR–D2R hetero-
tetramer and AC5 requires the optimal quaternary structure of
the heterotetramer. When BiFC experiments were performed in
the presence of CGS21680 (100 nM, Fig. 3e, bottom panel) or
quinpirole (1 μM, Fig. 3f, bottom panel), the pattern of interfering
synthetic peptides changed: In addition to TM5 and TM6 of
A2AR and D2R, TM7 of A2AR and TM2 of D2R decreased
ﬂuorescence complementation in the presence of CGS21680 and
quinpirole, respectively, while TM1 of A2AR and D2R were no
longer effective (Fig. 3e, f).
We then investigated the involvement of TMs of AC5 TMs in
the oligomerization with A2AR–D2R heteromers. Since the
structure of M1 and M2 domains of any AC isoform is unknown,
we used ﬁve commonly used algorithms to predict their most
probable TMs (Supplementary Table 1). All algorithms predicted
the same six TMs for the M2 domain (TM 7 to TM 12), but there
was discrepancy on the predicted TMs of the M1 domain. Taking
into account the orientation of the predicted TM helices, only
Uniprot and TOPCONS solutions were compatible with the well-
established intracellular N-terminal and C-terminal domains of
AC57. First, TM peptides mimicking right-oriented TMs derived
from Uniprot predictions (abbreviated TM1 to TM12) were
tested for their ability to destabilize complementation in HEK-
293T cells expressing AC5-nYFP, A2AR-cYFP, and D2R (Fig. 4a),
as well as AC5-nYFP, D2R-cYFP and A2AR (Fig. 4b). In the
absence of agonists, pretreatment of cells with TM1 or
TM12 signiﬁcantly decreased complementation between AC5
and A2AR, while TM5 showed a small but not signiﬁcant decrease
(Fig. 4a, top panel). Similarly, pretreatment with TM6 or
TM12 signiﬁcantly decreased complementation between AC5
and D2R while TM5 again showed a small but not signiﬁcant
decrease (Fig. 4b, top panel). Remarkably, when BiFC
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Fig. 2 Functional A2AR–D2R heterotetramers in transfected cells. a Quantiﬁcation from PLA experiments (see Supplementary Fig. 1) performed in HEK-293T
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were incubated overnight with vehicle or pertussis toxin (PTX; 10 ng/ml), or for 2 h with cholera toxin (CTX; 100 ng/ml), and exposed to CGS21680
(CGS; 100 nM) or quinpirole (Q; 1 μM) in the absence or in the presence of forskolin (Fk; 0.5 μM), respectively; values are expressed as percentage over
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experiments were performed in the presence of CGS21680 (100
nM, Fig. 4a, bottom panel) or quinpirole (1 μM, Fig. 4b, bottom
panel), the pattern of interfering synthetic peptides dramatically
changed. When receptors were activated, TM1, TM2, TM3, TM5
and TM6 signiﬁcantly decreased ﬂuorescence complementation
between AC5-nYFP and A2AR-cYFP and between AC5-nYFP and
D2R-cYFP. The results imply a major rearrangement of the
membrane-spanning domains of the activated pre-coupled
complex with an increase in the number of TMs of AC5 directly
or indirectly involved in the oligomerization with the A2AR–D2R
heterotetramer.
Opposite-oriented TM peptides, abbreviated as TM2n, TM3n,
TM4n, TM5n and TM6n, were tested to examine the speciﬁcity of
their destabilizing effect (see Supplementary Table 2), which
should insert in the membrane in the opposite direction and act
as scrambled control peptides. The peptides were tested in HEK-
293T cells expressing AC5-nYFP, A2AR-cYFP, and D2R (Fig. 4c)
as well as AC5-nYFP, D2R-cYFP, and A2AR (Fig. 4d) in the
absence or in the presence of agonists. The same as TM4, TM4n
did not have a signiﬁcant effect, and TM2n, TM3n and TM6n did
behave as negative controls to their opposite-oriented peptides,
since they did not decrease AC5-nYFP-A2AR-cYFP or AC5-
nYFP-D2R-cYFP complementation in the absence (Fig. 4c, d, top
panels) or in the presence (Fig. 4c, d, bottom panels) of agonists.
Intriguingly, both TM5 and the opposite-oriented TM5n were
able to decrease AC5-nYFP-A2AR-cYFP and AC5-nYFP-D2R-
cYFP complementation (Fig. 4c, d). Importantly, TM5 and TM5n
had the lowest hydrophobicity as compared to all the other
putative TM sequences (Supplementary Table 1), decreasing the
probability of being embedded in the membrane bilayer17. This
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with 0.5 μg of A2AR-Rluc cDNA and increasing amounts of AC5-YFP cDNA (0.3–2.5 μg) not co-transfected (a) or co-transfected (c) with D2R cDNA (0.5
μg), or with 0.75 μg of D2R-Rluc cDNA and increasing amounts of AC5-YFP cDNA (0.3–2.5 μg) not co-transfected (b) or co-transfected (d) with A2AR
cDNA (0.4 μg); the relative amount of BRET is given as a function of 1000× the ratio between the ﬂuorescence of the acceptor (YFP) and the luciferase
activity of the donor (Rluc) and expressed as milli BRET units (mBU) (6–8 experiments, with duplicates, grouped as a function of the amount of BRET
acceptor). e, f BiFC experiments in HEK-293T cells transfected with AC5-nYFP (0.75 μg), A2AR-cYFP (0.5 μg) and D2R (0.75 μg) cDNA (e) or AC5-nYFP
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530 nm and values are expressed as arbitrary ﬂuorescent units (n= 8, with triplicates); *, ** and *** represent signiﬁcantly lower values as compared to
control values (p < 0.05, p < 0.01 and p < 0.001, respectively; one-way ANOVA followed by Dunnett’s multiple comparison tests). Results are always
represented as means ± SEM
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could indicate that the AC5 325–345 amino acid sequence forms
part of the second intracellular loop (IL2), which could establish
direct or indirect intermolecular interactions with the A2AR-D2R
heteromer. Then, the 348–368 aa sequence predicted by the
TOPCONS algorithm (TM 5b in Supplementary Table 1), which
has the right orientation, becomes a very plausible TM that could
interact with the A2AR–D2R heterotetramer. In fact, TM5b
peptide signiﬁcantly decreased AC5-nYFP-A2AR-cYFP or AC5-
nYFP-D2R-cYFP complementation in the absence or in the
presence of agonists (Fig. 4c,d). In agreement with this
interpretation, a scrambled TM5-TM5n peptide (AC5-TM5s in
Supplementary Table 2) did not decrease AC5-nYFP-A2AR-cYFP
or AC5-nYFP-D2R-cYFP complementation in the absence of
ligands (93 ± 7, and 95 ± 6%, respectively, in means ± SEM and
expressed as percentage of change of ﬂuorescent values without
peptide; n= 9, with triplicates). As additional controls, we also
tested AC5 TM1 to TM12 peptides on A2AR-nYFP-D2R-cYFP
complementation and all the D2R TM and A2AR TM peptides
on AC5-nYFP-A2AR-cYFP and AC5-nYFP-D2R-cYFP com-
plementation, respectively, in the absence of ligands; no
changes in BiFC were observed under any condition
(Supplementary Fig. 5). Considering TM 1, TM 2, TM 3, TM
4, TM 5b, and TM 6 as the six putative TMs of the M1 domain
of AC5, altogether these results indicate that TM 1 and TM 6, as
well as IL2 and TM 5b, are involved in pre-coupling of A2AR-
D2R heterotetramer and AC5 in the absence of agonists. Upon
A2AR or D2R activation there is a rearrangement with an
apparent participation of almost all TMs of the M1 domain.
Two A2AR–D2R heterotetramers and two AC5 molecules. It
seems reasonable to hypothesize that the membrane-spanning
domains of AC5 are formed by two interacting antiparallel six-
helix-bundle domains (M1–M2) with an elliptical ring shape7. In
the absence of ligands, since it is not feasible that TM 1 from both
A2AR and D2R interact simultaneously with the same TM 5 or
TM 12 or the same IL2 of a single AC5 molecule, this suggests the
presence of two AC5 molecules simultaneously binding to the
A2AR–D2R heterotetramer in complex with Gi and Gs, possibly
with TM1 of D2R and TM 1 of A2AR interacting speciﬁcally with
TM 1 and TM 6 of AC5, respectively (Fig. 4e). The ability of
peptides that mimic TM 5, TM 12, and IL2 of AC to destabilize
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Fig. 4 Involvement of AC5 TMs in A2AR-D2R heterotetramer-AC5 oligomerization. a–d BiFC experiments in HEK-293T cells transfected with AC5-nYFP
(0.75 μg), A2AR-cYFP (0.5 μg) and D2R (0.75 μg) cDNA (a, c) or AC5-nYFP (0.75 μg), D2R-cYFP (0.75 μg) and A2AR (0.4 μg) cDNA (b, d); cells were
treated for 4 h with medium (dotted lines) or 4 μM of indicated TM peptides predicted from Uniprot algorithm (numbered 1–12) (a, b) or control peptides
(numbered 2n−6n and 5b; see text) (c, d), before addition of medium, CGS21680 (CGS; 100 nM) or quinpirole (Q; 1 μM); ﬂuorescence was detected at
530 nm and values (in means ± SEM) are expressed as arbitrary ﬂuorescent units (n= 8, with triplicates); *, ** and *** represent signiﬁcantly lower values
as compared to control values (p < 0.05, p < 0.01, and p < 0.001, respectively; one-way ANOVA followed by Dunnett’s multiple comparison tests). e–g
Schematic slice-representations of A2AR–D2R heterotetramer-AC5 models: heterotetramer coupled with two AC5 molecules in the absence (e) and in the
presence (f) of agonists; extension of the agonist-bound complex with a second A2AR–D2R heterotetramer, with simultaneous binding of both Gαs and Gαi
to the central C1 and C2 domains of AC5 (g). Schematic slice-representation viewed from the extracellular side of the A2AR–D2R heterotetramer in
complex with Gs, Gi, and AC5 in the absence and presence of agonists are shown in Supplementary Fig. 6
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oligomerization between AC5 and the A2AR–D2R heterotetramer
might depend on an indirect modiﬁcation of their discrete
asymmetrical interfaces.
It is well established that the Gα binding site for Gβγ overlaps
with the Gα binding sites for the effector, the cytoplasmic domains
C1 and C2 of AC. During G protein activation, Gβγ relative
movement promotes Gα binding to AC18,19. These swapping
interactions can take place within the frame of the A2AR–D2R
heterotetramer with two AC5 molecules binding simultaneously to
Gs and Gi in the complex (Fig. 4e, f). The rearrangement of TM
interfaces between the A2AR–D2R heterotetramer and AC5 upon
receptor activation occurs simultaneously with the rearrangement
of the Gβγ subunit, by its established stable coupling with the NT of
AC516, which facilitates the interaction between the Gα subunit and
its corresponding catalytic AC5 domain. This rearrangement in the
frame of the heteromer gives a computational molecular model of
activated complex schematized in Fig. 4f. Details about the
model are shown in Supplementary Fig. 6. However, within the
frame of the constraints imposed by a pre-coupled A2AR–D2R
heterotetramer-Gs-Gi-AC5 complex, a single A2AR–D2R hetero-
tetramer cannot accomplish the model proposed by Dessauer et al.8,
in which one Gs and one Gi bind simultaneously to one single AC5
(see below). Therefore, we propose that AC5 should oligomerize
with an additional A2AR–D2R heterotetramer (Fig. 4g). The results
with interfering peptides, together with the proposed simultaneous
binding of Gs and Gi to AC5, suggest a minimal functional complex
composed of two A2AR–D2R heterotetramers and two AC5
molecules (Fig. 4g).
The canonical Gs–Gi antagonistic interaction. To corroborate
the proposed model we studied the functional characteristics of
the A2AR–D2R heterotetramer-AC5 complex in rat striatal neu-
ronal primary cultures, which express endogenous A2AR–D2R
heteromer complexes20. Furthermore, AC5 is the predominant
AC subtype in striatal neurons21. First, we analyzed by PLA the
expression of A2AR–D2R heteromers, as well as the ability of the
synthetic peptides mimicking the TMs of A2AR and D2R to
modify the quaternary structure of the endogenous A2AR–D2R
heterotetramer. A2AR–D2R heteromers were observed as red
punctate staining in neuronal cells (Fig. 5a, b). As expected,
pretreatment of cells with TM4 and TM5 of A2AR and D2R, but
not with TM6 or with TM7, produced a signiﬁcant decrease in
the number of red spots per cell (Fig. 5b, c). These results
mirrored those obtained in HEK-293T cells (see Fig. 2a and
Supplementary Fig. 3), conﬁrming the same TMs 4/5 interface of
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Fig. 5 A2AR-D2R heterotetramer expression in striatal neurons in culture. Proximity ligation assay (PLA) in rat striatal primary cultures. a, c Confocal
microscopy images (superimposed sections) are shown in which A2AR-D2R heteromers appear as red spots. Primary cultures were treated for 4 h with
medium (a) or 4 μM of indicated TM peptides (numbered 1–7) of A2AR or D2R (c); cell nuclei were stained with DAPI (blue); scale bars: 20 μm. b
Quantiﬁcation from PLA experiments: values (in means ± SEM) are expressed as the ratio between the number of red spots and the number of cells
showing spots (r) (20–30 neurons from three independent preparations); % values represent the percentage of cells showing one or more red spots; ***p
< 0.001, as compared to control (one-way ANOVA followed by Dunnett’s multiple comparison tests)
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A2AR–D2R heteromers in striatal cells and that TM6 does not
destabilize heterodimerization. PLA experiments were also per-
formed with a recently characterized AC5 antibody22. A2AR-AC5
and D2R-AC5 complexes could be revealed as red punctate
staining in neuronal cells (Supplementary Fig. 7). Next, we
measured cAMP production to analyze the functional char-
acteristics of the A2AR–D2R heteromer and the effect of the
interfering peptides. As expected, CGS21680 (100 nM) increased
the synthesis of cAMP (Fig. 6a) and quinpirole (1 μM) decreased
forskolin-induced cAMP accumulation (Fig. 6a). Pertussis toxin,
selectively counteracted the ability of quinpirole to inhibit
forskolin-induced cAMP (Fig. 6b), while cholera toxin impeded
the activating effect of CGS21680 while leaving unaltered
quinpirole-induced inhibition of forskolin-induced AC5
activation (Fig. 6b). Simultaneous exposure to both agonists
demonstrated the ability of quinpirole to inhibit the effect of
CGS21680, revealing the canonical Gs–Gi interaction at AC5
(Fig. 6a).
Accumulation of cAMP was also determined in striatal cultures
upon exposure to ligands and interfering TM peptides. Pretreat-
ment with TM7 (as negative control) or with TM6 of A2AR or
D2R did not modify receptor signaling or the canonical
interaction (Fig. 6c, d). In contrast, although pretreatment with
TM4 and TM5 of A2AR (Fig. 6c) or D2R (Fig. 6d) did not modify
receptor signaling, it blocked the canonical interaction (Fig. 6c,
d). These results indicate that TMs that destabilize receptor
heteromerization do not disrupt the individual functional
interactions between the receptors and AC5, most probably
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Fig. 6 Canonical Gs–Gi antagonistic interaction in striatal neurons in culture. a, b cAMP production determined in rat striatal primary cultures incubated
overnight with vehicle (a) or with pertussis toxin (PTX; 10 ng/ml), or for 2 h with cholera toxin (CTX; 100 ng/ml) (b), and exposed to CGS21680 (CGS;
100 nM), quinpirole (Q; 1 μM) or both in the absence or in the presence of forskolin (Fk; 0.5 μM), respectively. c–e cAMP production determined in rat
striatal primary cultures incubated 4 h with 4 μM of indicated TM peptides of A2AR (c), D2R (d), or AC5 (e) and exposed to agonists as in a, b. Values (in
means ± SEM) are expressed as percentage of cAMP accumulation in non-treated cells (basal) (n= 5–7, with triplicates); ###p < 0.001, as compared to
basal values; ** and ***p < 0.01 and p < 0.001 as compared to Fk, respectively; &, &&&p < 0.05 and p < 0.001 as compared to CGS, respectively; one-way
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because of stable pre-coupling between the G proteins and AC5,
as recently demonstrated for the speciﬁc Gαolfβ2γ7-AC5 complex
in the rodent striatum22. Nevertheless, the peptides that
destabilize receptor heteromerization alter the correct coupling
of AC5 to the complex that allows the simultaneous binding of
Gαs and Gαi subunit to AC, impeding the canonical interaction.
In conclusion, A2AR–D2R heteromerization is a necessary
condition for the canonical antagonistic interaction between
Gs-coupled A2AR and Gi-coupled D2R at AC in striatal neurons
in culture. In agreement with this conclusion, cAMP accumula-
tion induced by CGS21680 was not counteracted by an agonist of
dopamine D4R, which does not heteromerize with A2AR23
(Supplementary Fig. 8). Finally, pretreatment of striatal cultures
with interfering peptides TM1, TM6 or TM12 of AC5 did not
change receptor signaling but also blocked the canonical
interaction, while TM10 was ineffective (Fig. 6e). These results
conﬁrm the involvement of the AC5 subtype in striatal cultures
and indicate that these AC5 TM peptides are not able to
destabilize the interactions between AC5 and the receptors but
induce an alteration of the quaternary structure of the complex
that impedes the simultaneous binding of Gαs and Gαi subunit to
AC5, the canonical interaction. Thus, the correct intermolecular
interaction between AC5 and the A2AR–D2R heterotetramer is
also a necessary condition for the presence of the canonical Gs–Gi
interaction at AC5.
The ability of quinpirole to reduce cAMP accumulation
induced by CGS21680 implies that Gi acts on a Gs-activated
AC5. Thus, simultaneous binding of Gsα to the C2 domain and
Giα to the C1 domain of a single AC5 must occur8. This, in fact,
agrees with the suggested complex of two A2AR–D2R hetero-
tetramers that simultaneously bind to the same AC5 molecule
(see Fig. 4g). In this model AC5 acts as a link between two
heterotetramers, which makes compatible the antagonistic
canonical interaction between Gsα and Giα activated proteins
at the same AC5 molecule. Moreover, the membrane-spanning
M1 and M2 domains of AC5 can accommodate between the two
A2AR–D2R heterotetramers (Supplementary Fig. 6), providing the
frame for the series of experimentally determined TM contacts
between A2AR, D2R, and AC5 (see above). However, with the
model that includes two A2AR–D2R heterotetramers and two AC5
molecules (Fig. 4g), only one AC5 simultaneously interacts with
Gsα and Giα. This would imply that quinpirole could only
produce a partial inhibition of CGS21680-induced cAMP
accumulation, while the results showed in Fig. 5a–e demonstrate
that quinpirole produces an almost complete blockade. We
therefore propose that the minimal functional quaternary
structure (see Fig. 4g) forms a linearly arranged high-order
oligomeric structures (Supplementary Fig. 6e).
Discussion
Striatal A2AR and D2R are known to form functionally and
pharmacologically signiﬁcant heteromers that modulate basal
ganglia function10. Here, we demonstrate the existence of inter-
molecular interactions between A2AR, D2R, and AC5 with the
emergence of functional A2AR–D2R heterotetramer-AC5 com-
plexes. These complexes sustain the canonical Gs–Gi interaction
at the AC level, the ability of a Gi-coupled GPCR to counteract
AC activation mediated by a Gs-coupled GPCR.
We ﬁrst identiﬁed the symmetrical TM 6 homodimer and TMs
4/5 heterodimer interfaces in the A2AR–D2R heterotetramer from
results of BiFC experiments obtained with speciﬁc TM peptides
mimicking TM receptor domains. While BiFC complex forma-
tion under in vitro conditions has been considered to be essen-
tially irreversible24, several studies indicate that under in vivo
conditions BiFC complex formation can be reversible25–27. The
present results provide additional support to that reversibility,
which lies on the speciﬁcity of the peptide approach, demonstrated
by the qualitative identical results from BiFC, PLA, and cAMP
accumulation experiments. From these results, we could develop a
computational model, where only the two internal protomers
participate in the heteromeric interface and the two external pro-
tomers participate in the homomeric interface of the A2AR–D2R
heterotetramer. A pattern of similar symmetrical interfaces of
GPCR homomers and heteromers involving speciﬁc TMs has
emerged from several studies also using TM interfering peptides,
cross-linking techniques or crystallographic analysis (see ref.6, for
review). The consistent results we obtained with interfering pep-
tides in experiments with biosensor-fused receptors in transfected
cells and with native receptors in striatal neurons in culture, pro-
vide strong support for the involvement of TM 6 in the homomeric
interfaces and TM 4 and TM 5 in the heteromeric interface of the
A2AR–D2R heterotetramer in its natural environment. The differ-
ences in the apparent interfaces of A2AR and D2R homomers here
reported as compared to previous studies (TM 6 versus TMs 4 or/
and 5)28,29, could be due to the different experimental approaches
and, most likely, due to the presence of heteromeric partner
receptors that inﬂuence the TM interfaces. The fact that rearran-
gement of TM 6 constitutes main ligand-induced conformational
changes that determine G protein activation and modulation of
ligand afﬁnity30, provides a frame for the understanding of allos-
teric communications through the protomers in GPCR oligomers4–
6. Thus, in our constructed models, TM 6 in the inactive closed
conformation of the unliganded protomer interacts with TM 6 in
the active open conformation of the G protein-bound protomer
(Supplementary Fig. 4).
An important conclusion from this study is that the non-
activated or agonist-activated A2AR–D2R heterotetramer is able to
stablish different molecular interactions with AC5. By using
speciﬁc interfering peptides, we demonstrate that these interac-
tions involve TMs from the receptors and the AC5. The speciﬁ-
city of the peptide approach was unambiguously demonstrated
with their orientation-dependent selectivity on their ability to
destabilize the asymmetrical interfaces between AC5 and the
receptors. The differential effect of interfering TM peptides in the
absence and presence of agonists implies a major rearrangement
of the membrane-spanning domains of the activated pre-coupled
complex with an increase in the number of TMs of AC5 directly
or indirectly involved in the oligomerization with the A2AR–D2R
heterotetramer during agonist exposure. This rearrangement
could be driven by the agonist-induced relative movement of the
Gβγ subunit away from the helical-domain of the Gα subunit,
simultaneously pulling the NT domain of AC516 and facilitating
the interaction of its catalytic domains with the corresponding Gα
subunit18,19. This key role of the G protein in determining
changes in the quaternary structure of the A2AR–D2R
heterotetramer-AC5 complex upon receptor activation would
agree with the recently described stable pre-coupling of striatal
Golf and AC522 and the here described less stable interactions
between TMs of AC5 and A2AR and D2R.
Probably the most signiﬁcant conclusion of the study is that the
A2AR–D2R heterotetramer-AC5 complex sustains the canonical
antagonistic Gs–Gi interaction at the AC level. This was also
demonstrated with speciﬁc interfering TM peptides, by the very
selective ability of the TM peptides that mimic the heteromeric
interface in the A2AR–D2R heterotetramer to block the canonical
antagonistic interaction in striatal neurons in culture. The sig-
niﬁcant control of A2AR signaling by D2R implied that most A2AR
that signal through AC5 are forming heteromers with D2R in this
neuronal preparation. Previous studies indicate that the same
situation occurs in vivo in the striatum, where the pharmacolo-
gical or genetic blockade of D2R disinhibits adenosine-mediated
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activation of AC in the striato-pallidal neuron31. In fact, A2AR
blockade counteracts most biochemical and behavioral effects
induced by interruption of D2R signaling31. In complete agree-
ment are also the results obtained by Lee et al. with AC5
knockout mice21, which show that AC5 is the principal AC
integrating signals from A2AR and D2R in the striatum and that
the signaling cascade involving AC5 is essential for the behavioral
effects of D2R antagonists, and therefore antipsychotic drugs. The
efﬁcient D2R-mediated antagonism of A2AR-mediated AC acti-
vation, however, cannot be explained by a minimal functional
structure of an A2AR–D2R heterotetramer-AC5 complex that can
sustain a canonical Gs–Gi interaction at AC, which is composed
of two A2AR–D2R heterotetramers and two AC5 molecules. Such
a complex would not allow the D2R agonist to exert the almost
complete inhibition of A2AR agonist-mediated cAMP revealed in
the experiments on striatal neurons in culture. In fact, this qua-
ternary structure suggests the possible formation of zig-zagged
arranged high-order oligomeric structures (Supplementary
Fig. 6), as proposed for other GPCRs, including D2R and rho-
dopsin homomers20,32. To our knowledge, these are the ﬁrst data
suggesting higher-order linear arrangements of GPCR heteromers
and effectors.
The present study represents a proof of concept of the signiﬁcant
functional role of GPCR heteromers within a signalosome, since it
demonstrates that GPCR heteromers provide the frame for bio-
chemical interactions previously thought to be independent of
intermolecular receptor–receptor interactions, on classical receptor
cross-talk at the second-messenger level33. Therefore, we postulate
that pre-coupling should not only apply to other Gs–Gi–AC-cou-
pled heteromers, but also to heteromers coupled to other G pro-
teins and effectors, such as the well-established Gi–Gq-coupled
metabotropic glutamate receptor mGlu2 receptor-serotonin 5-
HT2A receptor heteromer34, which could be pre-coupled to
potassium channels35. At a more general level, the present results
represent a very signiﬁcant support to the still controversial con-
cepts of GPCR pre-coupling and oligomerization.
Methods
Vectors and fusion proteins. Sequences encoding amino acid residues 1–155 and
156–238 of YFP Venus protein were subcloned into the pcDNA3.1 vector to obtain
the YFP Venus hemi-truncated proteins (pcDNA3.1-cVenus or pcDNA3.1-nVenus
vectors). The cDNA constructs encoding human A2AR or D2R in pcDNA3 vectors
were subcloned in pRluc-N1 (PerkinElmer, Wellesley, MA) to generate A2AR-Rluc or
D2R-Rluc fusion proteins on the C-terminal end or were subcloned to be in-frame
with restriction sites of pcDNA3.1-cVenus or pcDNA3.1-nVenus vectors to give the
plasmids that express proteins fused to hemi-YFP Venus on the C-terminal end
(A2AR-cYFP, D2R-cYFP, A2AR-nYFP or A2AR-nYFP). Human AC5 cDNA was
ampliﬁed without its stop codon using sense and antisense primers harboring unique
KpnI and EcoRV. The ampliﬁed fragment was subcloned to be in-frame with
restriction sites of pEYFP-N1 (enhanced yellow variant of GFP; Clontech, Heidel-
berg, Germany) or pcDNA3.1-nVenus vectors to give the plasmids that express AC5
fused to YFP or hemi-YFP Venus on the C-terminal end (AC5-YFP or AC5-nYFP).
Cell cultures and transfection. Primary cultures of striatal neurons were obtained
from fetal Sprague Dawley rats of 19 days. All experiments were carried out in
accordance with EU directives (2010/63/EU and 86/609/CEE) and were approved
by the Ethical Committee of the University of Barcelona. Striatal cells were isolated
as described elsewhere20 and plated at a conﬂuence of 40,000 cells/0.32 cm2. Cells
were grown in Neurobasal medium supplemented with 2 mM L-glutamine, 100 U/
ml penicillin/ streptomycin, and 2% (v/v) B27 supplement (GIBCO) in a 96-well
plate for 12 days. HEK-293T cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin, and 5% (v/v) heat inactivated fetal bovine serum (Invitrogen). HEK-
293T cells (ATCC, Manassas, VA) were transfected with the plasmids encoding
receptors by the PEI (PolyEthylenImine) method as previously described20.
TAT-TM peptides. Peptides with the sequence of transmembrane domains (TM) of
A2AR and D2R and putative TM peptides of AC5 fused to the HIV transactivator of
transcription (TAT) peptide (YGRKKRRQRRR) were used as oligomer-destabilizing
molecules. The cell-penetrating TAT peptide allows intracellular delivery of fused
peptides36. The TAT-fused TM peptide can then be inserted effectively into the
plasma membrane because of the penetration capacity of the TAT peptide and the
hydrophobic property of the TM moiety11. To obtain the right orientation of the
inserted peptide, the HIV-TAT peptide was fused to the C-terminus or to the N-
terminus as indicated. The amino acid sequences of the fusion peptides are shown in
Supplementary Table 2. Several algorithms were used to identify putative TMs in the
primary amino acid sequence of AC5 (Supplementary Table 1).
Bimolecular ﬂuorescence complementation. HEK-293T cells were transiently
co-transfected with the cDNA encoding a protein fused to nYFP and a protein
fused to cYFP. After 48 h, cells were treated or not with the indicated TM peptides
(4 μM) for 4 h at 37 °C. The time of incubation and concentration of TM peptides
were chosen from results of concentration-dependent and time-dependent
response experiments of the possible BiFC destabilization by all seven TM peptides
of the A2AR in HEK-293T cells transfected with A2AR-nYFP and A2AR-cYFP
(Supplementary Fig. 3). The same parameters were applied with D2R and AC5 TM
peptides and in PLA and cAMP experiments. To quantify protein reconstituted
YFP Venus expression, cells (20 μg protein; 50,000 cells/well) were distributed in
96-well microplates (black plates with a transparent bottom, Porvair, King’s Lynn,
UK), and emission ﬂuorescence at 530 nm was monitored in a FLUOstar Optima
Fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a high-
energy xenon ﬂash lamp, using a 10-nm bandwidth excitation ﬁlter at 400 nm
reading. Protein ﬂuorescence expression was determined as the ﬂuorescence of the
sample minus the ﬂuorescence of cells not expressing the fusion proteins (basal).
Cells expressing protein-cVenus and nVenus or protein-nVenus and cVenus
showed similar ﬂuorescence levels than non-transfected cells.
Bioluminescence resonance energy transfer assay. HEK-293T cells were tran-
siently cotransfected with a constant amount of expression vectors encoding for
proteins fused to RLuc and with increasing amounts of the expression vectors
corresponding to proteins fused to YFP. To quantify protein-YFP expression, cells
(20 μg protein, around 50,000 cells/well) were distributed in 96-well microplates
(black plates with a transparent bottom), and ﬂuorescence was read in a Fluo Star
Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a
high-energy xenon ﬂash lamp, using a 10-nm bandwidth excitation ﬁlter at 400 nm
reading. Fluorescence expression was determined as ﬂuorescence of the sample
minus the ﬂuorescence of cells only expressing the BRET donor. For BRET mea-
surements, the equivalent of 20 μg of cell suspension was distributed into 96-well
microplates (Corning 3600, white plates; Sigma) and 5 μM coelenterazine H
(Molecular Probes, Eugene, OR) was added. The readings were taken 1 min later
using a Mithras LB 940. The integration of the signals detected in the short-
wavelength ﬁlter at 485 nm and the long-wavelength ﬁlter at 530 nm was recorded.
To quantify protein-RLuc expression luminescence, readings were performed 10
min after adding 5 μM of coelenterazine H. Fluorescence and luminescence of each
sample were measured before every experiment to conﬁrm similar donor expres-
sions (approximately 100,000 bioluminescence units) while monitoring the
increase in acceptor expression (1000 to 30,000 ﬂuorescence units). The net BRET
is deﬁned as [(long-wavelength emission)/(short-wavelength emission)]− Cf,
where Cf corresponds to [(long-wavelength emission)/(short-wavelength emis-
sion)] for the donor construct expressed alone in the same experiment. BRET is
expressed as milliBRET units (mBU; net BRET x 1000). Data were ﬁtted to a
nonlinear regression equation, assuming a single-phase saturation curve with
GraphPad Prism software (San Diego, California, US). BRETmax and BRET50
values were obtained from the analysis of the BRET saturation curves. BRET50 is a
magnitude related to the afﬁnity of the protein-protein interaction, with low values
representing high afﬁnity (as in the present results; Fig. 2a–d).
Proximity ligation assay. HEK293T cells or neuronal primary cultures were
grown on glass coverslips and ﬁxed in 4% paraformaldehyde for 15 min, washed
with phosphate-buffered saline (PBS) containing 20 mM glycine, permeabilized
with the same buffer containing 0.05% Triton X-100, and successively washed with
TBS. Heteromers and AC5-receptor complexes were detected using the Duolink II
in situ PLA detection Kit (OLink; Bioscience, Uppsala, Sweden) following sup-
plier’s instructions. A mixture of the primary antibodies [mouse or rabbit anti-
A2AR antibodies (1:100; 05-717 and AB1559P, Millipore, Darmstadt, Germany),
rabbit anti-D2R antibody (1:100; AB5084P, Millipore) and the recently character-
ized mouse anti-AC5 antibody22 (1:50)] was used to detect A2AR–D2R heteromers
together with PLA probes detecting mouse or rabbit antibodies. The speciﬁcity of
the same A2AR and D2R antibodies for PLA assays has been previously demon-
strated37. Then, samples were processed for ligation and ampliﬁcation with a
Detection Reagent Red and were mounted using a DAPI-containing mounting
medium. Samples were analyzed in a Leica SP2 confocal microscope (Leica
Microsystems, Mannheim, Germany) equipped with an apochromatic 63X oil-
immersion objective (1.4 numerical aperture), and 405-nm and 561-nm laser lines.
For each ﬁeld of view a stack of two channels (one per staining) and 4 to 6 Z-stacks
with a step size of 1 μm were acquired. Images were opened and processed with
Image J software (National Institutes of Health, Bethesda, MD). Quantiﬁcation of
the total number of red dots versus total cells (blue nuclei) was counted on the
maximum projections of each image stack. After getting the projection, each
channel was processed individually.
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Determination of cAMP. Homogeneous time-resolved ﬂuorescence energy
transfer (HTRF) assays were performed using the Lance Ultra cAMP kit (Perki-
nElmer), based on competitive displacement of a europium chelate-labeled cAMP
tracer bound to a speciﬁc antibody conjugated to acceptor beads. We ﬁrst estab-
lished the optimal cell density for an appropriate ﬂuorescent signal. This was done
by measuring the TR-FRET signal as a function of forskolin concentration using
different cell densities. The forskolin dose-response curves were related to the
cAMP standard curve, to establish which cell density provides a response that
covers most of the dynamic range of the cAMP standard curve. Cells (1000–2000
HEK-293T or 4000 to 5000 primary cultures per well) growing in medium con-
taining 50 μM zardeverine were pre-treated with toxins or the corresponding
vehicle in white ProxiPlate 384-well microplates (PerkinElmer) at 25 °C for the
indicated time and stimulated with agonists for 15 min before adding 0.5 μM
forskolin or vehicle and incubating for an additional 15 min period. Fluorescence at
665 nm was analyzed on a PHERAstar Flagship microplate reader equipped with
an HTRF optical module (BMGLab technologies, Offenburg, Germany).
Computational models. Inactive models of the human A2AR and D2R were
constructed based on the crystal structures of inactive A2AR (PDB id 5IU4)38 and
D3R (PDB id 3PBL)39, respectively. The “active” conformations of A2AR bound to
Gs and D2R bound to Gi were modeled by incorporating the active features of the
crystal structure of β2-adrenoceptor in complex with Gs (PDB code 3SN6)30. The
globular α-helical domain of the α-subunit was modeled in the “closed” con-
formation, using the crystal structure of either Gsα (PDB id 1AZT)40 or Giα (PDB
id 3UMR)41. The absence of crystal structures of the M1 and M2 domains of AC or
close protein templates impede their inclusion on the models. Nevertheless, the
results with interfering peptides provide signiﬁcant information about the putative
location of the TM segments, which have been considered to form an antiparallel
six-helix bundle with an elliptical ring shape as most of the membrane proteins.
The structure of the intracellular C1 and C2 domains of AC in complex with Gsα
and Giα was modeled as in the crystal structure of C1 and C2 in complex with Gsα
(PDB id 1CUL)42. All homology models were built using Modeller 9.1643. The
structure of A2AR and D2R heterodimer, using the TMs 4/5 interface, was modeled
as in the oligomeric structure of the β1-adrenoceptor (PDB code 4GPO)44, whereas
the structures for A2AR (inactive and Gs-bound “active” A2AR) and D2R (inactive
and Gi-bound “active” D2R) homodimers were modeled using molecular dynamics
simulations (see Supplementary Fig. 2) due to the absence of crystal structures of
oligomers using exclusively the TM6 interface11.
Statistical information. One-way ANOVA followed by Dunnett’s or Tukey’s
multiple comparison tests were used for statistical comparisons between different
groups of results. Number of experiments and replications as well as the statistical
results are shown in the corresponding ﬁgure legends.
Data availability. All data that support the ﬁndings of this study are available from
the corresponding author upon reasonable request.
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